Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Defibrotide - Jazz Pharmaceuticals

X
Drug Profile

Defibrotide - Jazz Pharmaceuticals

Alternative Names: Defibrotide sodium; Defitelio; Fraction P; JZP-381; Noravid; NS 73; Prociclide

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gentium
  • Developer Fukushima Medical University; Gentium; Jazz Pharmaceuticals plc; Nippon Shinyaku; Swedish Orphan Biovitrum; University of California at San Francisco
  • Class Antithrombotics; Nucleotide aptamers; Polydeoxyribonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Heparanase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Veno-occlusive disorders; Thrombotic thrombocytopenic purpura; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Veno-occlusive disorders
  • Phase II Graft-versus-host disease; Neurological disorders; Thrombotic microangiopathies
  • Market Withdrawal Deep vein thrombosis; Thrombosis
  • No development reported Diabetic nephropathies; Multiple myeloma

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for preclinical development in Graft-versus-host-disease(Prevention) in Italy (IV, Infusion)
  • 11 Dec 2021 Efficacy and safety data from the phase III HARMONY trial in Veno-occlusive disorders presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
  • 20 Apr 2021 Jazz Pharmaceuticals terminates phase II trial in Neurological disorders in USA as primary endpoints were unlikely to be met (NCT03954106)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top